Mascarin Alba, Valverde Ibai E, Mindt Thomas L
Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland.
Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland.
ChemMedChem. 2016 Jan 5;11(1):102-7. doi: 10.1002/cmdc.201500468. Epub 2015 Nov 23.
Radiolabeled derivatives of the peptide neurotensin (NT) and its binding sequence NT(8-13) have been studied as potential imaging probes and therapeutics for NT-1-receptor-positive cancer. However, a direct comparison of reported NT analogues, even if radiolabeled with the same radionuclide, is difficult because different techniques and models have been used for preclinical evaluations. In an effort to identify a suitable derivative of NT(8-13) for radiotracer development, we herein report a side-by-side in vitro comparison of radiometallated NT derivatives bearing some of the most commonly reported amino acid substitutions in their sequence. Performed investigations include cell internalization experiments, determinations of receptor affinity, measurements of the distribution coefficient, and blood serum stability studies. Of the [(177)Lu]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-labeled examples studied, analogues of NT(8-13) containing a short hydrophilic tetraethylene glycol (PEG4 ) spacer between the peptide and the radiometal complex, and a minimum number of substitutions of amino acid residues, exhibited the most promising properties in vitro.
肽神经降压素(NT)及其结合序列NT(8 - 13)的放射性标记衍生物已被研究作为NT - 1受体阳性癌症的潜在成像探针和治疗剂。然而,即使使用相同的放射性核素进行放射性标记,已报道的NT类似物之间的直接比较也很困难,因为临床前评估使用了不同的技术和模型。为了确定适合用于放射性示踪剂开发的NT(8 - 13)衍生物,我们在此报告了在序列中带有一些最常报道的氨基酸取代的放射性金属化NT衍生物的体外并列比较。进行的研究包括细胞内化实验、受体亲和力测定、分配系数测量和血清稳定性研究。在所研究的[(177)Lu]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)标记的实例中,在肽与放射性金属络合物之间含有短亲水性四甘醇(PEG4)间隔基且氨基酸残基取代最少的NT(8 - 13)类似物在体外表现出最有前景的特性。